SomaLogic announces deployment of SOMAscan™ assay to University of Houston and Sidra Medical and Research Center


SomaLogic announced today that the University of Houston (Houston, TX) and Sidra Medical and Research Center (Doha, Qatar) are the latest academic centers to deploy SomaLogic’s proprietary SOMAscan assay to accelerate protein biomarker discovery and development across multiple life science research studies in their respective institutions.

Ena Wang, MD, Division Chief of Translational Medicine and Jean-Charles Gravel, PhD, Director of Deep Phenotyping Core facility will oversee the SOMAscan deployment at Sidra Medical and Research Center; and Chandra Mohan, MD, PhD, the Hugh Roy and Lillie Cranz Cullen Endowed Professor in Biomedical Engineering is directing the deployment at the University of Houston.

Compared to other current proteomic technologies, SomaLogic provides researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates over 1,000 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

“We are delighted that the University of Houston and Sidra Medical Research Center, under the capable leadership of Drs. Mohan, Wang and Gravel respectively, have joined a growing number of high quality biomedical research centers and scientists using our SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “We believe that the continued expansion of access to our technology will help accelerate critical new discoveries in biology and medicine.”

Other sites where the SOMAscan assay has been deployed include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, the University of Colorado Denver, the University of Manitoba’s Centre for Proteomics and Systems Biology, and the Weill Cornell Medical College in Qatar. Additional SOMAscan assay sites will be announced in the next several months.